Evotec partner Kazia Therapeutics Limited, an oncology-focused drug development company, announced the publication of positive pre-clinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evt801-pre-clinical-data-published-in-peer-reviewed-cancer-research-journal-6241